通过岩藻多糖调节肠道微生态改善化疗性肝损伤的机制研究

夏劲松; 陈笑容; 史芸溪; 王思琪; 史登晴; 焦春花

doi:10.70693/cjmsr.v1i2.1342

Authors

夏劲松南京医科大学
陈笑容南京医科大学
史芸溪南京医科大学
王思琪南京医科大学
史登晴南京医科大学
焦春花江苏省人民医院

DOI:

https://doi.org/10.70693/cjmsr.v1i2.1342

Keywords:

岩藻多糖；化疗性肝损伤；肠道微生态；肠肝轴

Abstract

本研究通过建立化疗性肝损伤小鼠模型，探讨岩藻多糖通过调节肠道微生态改善化疗性肝损伤的机制。实验采用C57BL/6小鼠，分为正常对照组、伊立替康模型组和岩藻多糖干预组。结果显示，岩藻多糖显著改善化疗性肝损伤小鼠的肠道微生态环境，表现为肠道菌群多样性和结构恢复，促进肠道及四肢血流循环，缓解肝脏、结肠、胸腺等多器官的组织病理学损伤。岩藻多糖干预组小鼠的一般状态、体重、进食量、血液免疫细胞水平及血清生化指标（如ALT、AST、LPS、炎性因子等）均优于模型组，炎症水平显著降低。研究表明，岩藻多糖通过肠肝轴途径改善化疗性肝损伤，为肿瘤化疗中肝损伤的防治提供了新方向，但其具体机制需进一步研究。

References

[1] THATISHETTY A V, AGRESTI N, O'BRIEN C B. Chemotherapy-induced hepatotoxicity [J]. Clin Liver Dis, 2013, 17(4): 671-86, ix-x.

[2] LIMAIEM F, BOURAOUI S. Chemotherapy-induced liver injury in metastatic colorectal cancer: about 48 cases [J]. Pan Afr Med J, 2018, 30: 198.

[3] 杨为杰, 陈鑫. 乳腺癌化疗性肝损伤的影响因素 [J]. 临床医学工程, 2021, 28(10).

[4] 马志刚, 徐京京, 刘艳艳. 维生素E防治大肠癌患者急性化疗性肝损伤的疗效分析 [J]. 黑龙江医学, 2016, 40(11).

[5] GRANDER C, ADOLPH T E, WIESER V, et al. Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease [J]. Gut, 2018, 67(5): 891-901.

[6] BAHIRWANI R, REDDY K R. Drug-induced liver injury due to cancer chemotherapeutic agents [J]. Semin Liver Dis, 2014, 34(2): 162-71.

[7] XUE M, LIANG H, JI X, et al. Effects of fucoidan on gut flora and tumor prevention in 1,2-dimethylhydrazine-induced colorectal carcinogenesis [J]. J Nutr Biochem, 2020, 82: 108396.

[8] HE S, PENG W B, ZHOU H L, et al. A Combination of Deep-Sea Water and Fucoidan Alleviates T2DM through Modulation of Gut Microbiota and Metabolic Pathways [J]. Pharmaceuticals (Basel), 2023, 16(3).

[9] CHIANG C S, LIN Y J, LEE R, et al. Combination of fucoidan-based magnetic nanoparticles and immunomodulators enhances tumour-localized immunotherapy [J]. Nat Nanotechnol, 2018, 13(8): 746-54.

[10] CALISTRI L, RASTRELLI V, NARDI C, et al. Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis [J]. World J Gastroenterol, 2021, 27(46): 7866-93.

[11] OLENNIKOV D N, KASHCHENKO N I, CHIRIKOVA N K. In Vitro Bioaccessibility, Human Gut Microbiota Metabolites and Hepatoprotective Potential of Chebulic Ellagitannins: A Case of Padma Hepaten® Formulation [J]. Nutrients, 2015, 7(10): 8456-77.

[12] MEUNIER L, LARREY D. Chemotherapy-associated steatohepatitis [J]. Ann Hepatol, 2020, 19(6): 597-601.